Published in Hepatitis Weekly, November 17th, 2008
"Eligible treatment-naive adults with genotype I infection, hepatitis C virus (HCV) RNA >800,000 IU/mL and body weight >85 kg were randomized to double-blind treatment with peginterferon alfa-2a at 1.80 or 270 mu g/week plus ribavirin at 1200 or 1600 mg/day for 48 weeks (four regimens were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.